Koh Furuta

Koh Furuta

Auto-generated profile, based on publicly available information

Koh Furuta

Chiba Medical Center , Chiba , Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2015 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
KIKatsuyoshi Ikeda
Katsuyoshi Ikeda
KIKiyoshi Ichihara
Kiyoshi Ichihara
THTeruto Hashiguchi
Teruto Hashiguchi
YHYoh Hidaka
Yoh Hidaka
DKDongchon Kang
Dongchon Kang
KFKoh Furuta
Koh Furuta
Background: A major concern in both the laboratory-medicine and research communities is the quality of human specimens for analysis. However, there is insufficient scientific evidence regarding optimal conditions for handling and storing routine specimens, especially those in liquid form. Thus, we investigated the stability of clinically relevant samples stored under various conditions. Materials and Methods: Ten clinical laboratories in Japan conducted analyses of the stability of post-clinical (left over after analysis) test samples in relation to temperature and storage duration. We examined serum, whole blood, and urine samples submitted to each laboratory for routine testing. In this study, at least 5 samples for each of 35 tests were analyzed at each laboratory. After completion of routine testing, specimens with sufficient residual volume and values between LL−R/2 (lower limit of reference interval) and UL+R/2 (upper limit) were divided into 300 μL aliquots, where R=UL − LL. Aliquots of serum specimens were stored at either room temperature (23°C), 4°C, −20°C, or −80°C without light exposure. Aliquots of whole blood and urine specimens were stored at either 23°C or 4°C. The storage time was either 1, 3, or 7 days. Average differences between pre- and post-storage test results were evaluated for each laboratory test by two-way ANOVA. F-values for between-day variations were used for judging the statistical significance of storage-related changes in test values, whereas the ratio of between-day SD to between-individual SD (one-fourth of reference interval) was used to indicate the practical significance of the change. Results and Conclusion: Sample denaturation is clearly temperature- and storage-duration dependent for almost all analytes. In general, specimens were most susceptible to denaturation at 23°C, then 4°C, −20°C, and −80°C. This study confirmed the accumulated routine, practice-based, detailed knowledge regarding specimen stability and will help to ensure the reliability of laboratory test results.

17 October 2022 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
RSRyo Shirakashi
Ryo Shirakashi
ZKZisis Kozlakidis
Zisis Kozlakidis
BYBirendra Kumar Yadav
Birendra Kumar Yadav
WNWayne Ng
Wayne Ng
JFJajah Fachiroh
Jajah Fachiroh
KFKoh Furuta
Koh Furuta
Calls to reduce or entirely remove the carbon footprint of ongoing activities, collectively termed as decarbonization, have become increasingly more vocal in health care with a number of recent, high profile consensus statements. These calls encourage the biobanking field, as one of the foundational health care research infrastructures, to consider decarbonization as a potential novel research area both in terms of the molecules and the equipment used in research. The current article provides a summary of the roundtable discussion during the 2022 ISBER Annual Meeting and Exhibits, highlighting the current knowledge gaps, challenges, and opportunities in this field. In particular, technological innovation, a greater awareness of the current situation, and behavioral change are important pieces of the puzzle to improving the future of decarbonization in biobanking, even if the eventually implemented routes between resource-abundant and resource-restricted settings might be distinctly different. This article sets the foundation for raising awareness of the subject and of subsequent steps that need to be undertaken.

15 December 2020 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
BYBirendra Kumar Yadav
Birendra Kumar Yadav
WNWayne Ng
Wayne Ng
JFJajah Fachiroh
Jajah Fachiroh
TTTatsuaki Tsuruyama
Tatsuaki Tsuruyama
KFKoh Furuta
Koh Furuta
Background: Biobankers have been unexpectedly involved in the pandemic of COVID-19 since early 2020. Although specific guidance was not available, the International Society for Biological and Environmental Repositories (ISBER) Best Practices and the ISO 20387 document have been utilized to deal with the pandemic disaster. The ISO experts and best practice experts in ISBER teamed up to share the available information and learn the experiences of biobanks concerning COVID-19 through organizing webinars, surveys, and town hall meetings. Four ISBER regional ambassadors (RAs) from the Indo-Pacific Rim (IPR) region were also actively involved at one of the town hall meetings. These RAs, who are from Australia, India, Indonesia, and Japan, and the Director-at-Large of the region, have summarized their experiences in this article. Materials and Methods: The ISBER Standards Committee COVID-19 Task Force has kindly provided the survey results. The extracted glossary from the results was categorized into 10 factors: (1) crisis management; (2) sample-related issues; (3) logistics-related issues; (4) equipment-related issues; (5) ethical, legal, and social implication-related issues; (6) operation-related issues; (7) personnel-related issues; (8) management-related issues; (9) infection-related issues; and (10) research-related issues. Each IPR RA has provided a case considering these 10 factors. Results and Discussion: Two key points have emerged from the scenarios, which are as follows: (1) impacts of the biobanks in low- and middle-income countries (LMICs) are similar to those in high-income countries (HICs) and (2) tolerance of the biobanks in LMICs is not so robust as those in HICs. Furthermore, communication strategies with internal and external stakeholders are critical for a biobank to manage this crisis. This article summarizes the impacts, indicates the opportunities that COVID-19 has brought to the biobank community, and highlights the usefulness of the network beyond biobank services. Lastly, the biobanks need to turn the challenges into opportunities to overcome the crisis.

19 June 2023 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
BYBirendra Kumar Yadav
Birendra Kumar Yadav
WNWayne Ng
Wayne Ng
HVHanh Vu
Hanh Vu
JFJajah Fachiroh
Jajah Fachiroh
TTTatsuaki Tsuruyama
Tatsuaki Tsuruyama
KFKoh Furuta
Koh Furuta
Biobanking is a relatively newly recognized and innovative branch of science, which includes the collection of samples and associated data from hospitals, diagnostic centers, and voluntary donations for biomedical and environmental research. It involves diverse stakeholders at the junction of society, science, ethics, law, and politics. A key element in the success of a biobank is the trust and support of public donors, clinicians, and scientists. To achieve trust, it is important to implement strategies that can increase biobank awareness in common people, and different types of communities. Biobank laws and regulations and transparent governance by the biobanks are also crucial to achieving public trust.

20 April 2022 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
YHYoung Bae Lee Hansen
Young Bae Lee Hansen
KFKoh Furuta
Koh Furuta
SDSridevi Devaraj
Sridevi Devaraj
FYFatma Meric Yilmaz
Fatma Meric Yilmaz
GNGunnar Nordin
Gunnar Nordin
Article Misleading nomenclature of units of WHO materials used for standardization of SARS COv-2 serology was published on April 20, 2022 in the journal Clinical Chemistry and Laboratory Medicine (CCLM) (volume 0, issue 0).

1 April 2025 in Biopreservation and Biobanking
Verified
Journal Article
Closed access
KFKoh Furuta
Koh Furuta
HVHanh Vu
Hanh Vu
DADaniel Adamek
Daniel Adamek
AAArmin Ahmadi
Armin Ahmadi
JBJerome Baudry
Jerome Baudry
KFKoh Furuta
Koh Furuta
This article provides an update on the current state of decarbonization efforts in biobanking, reflecting on the evolving discussions at the annual meetings of the International Society for Biological and Environmental Repositories (ISBER). Following roundtable discussions at the 2021 and 2023 meetings, the 2024 ISBER meeting, which was held in Melbourne, Australia, featured a symposium, workshop, and posters dedicated to decarbonization, highlighting its growing significance on a global scale. The introduction of the term “green biobanking” at this meeting marked a pivotal moment, revealing that current decarbonization efforts in biobanking are largely piecemeal and lack a comprehensive, strategic approach. The goal of this article is to clarify the concept of green biobanking and update the community on the latest developments, while carefully outlining potential pathways for future innovation without pressuring biobankers to adopt existing technologies. The discussion includes insights from experts across various sectors. These include experts from the World Health Organization, biobanks in high-income countries, and low- and middle-income countries, as well as from the Canadian academia, preservation technology, industry, artificial intelligence, and education sectors. The authors emphasize the need for collaboration among all stakeholders to drive the field forward through creative disruption and pave the way for a sustainable future in biobanking.